Cite
Paul A, Morawski J, Spinner DS, et al. Global HTA Assessments of Ultra-Orphan Products: A Case Study Of Eculizumab (Soliris) and Iduronate-2-Sulfatase (Elaprase). Value Health. 2014;17(7):A431doi: 10.1016/j.jval.2014.08.1098.
Paul, A., Morawski, J., Spinner, D. S., Doyle, J. J., Faulkner, E. C., & Ransom, J. F. (2014). Global HTA Assessments of Ultra-Orphan Products: A Case Study Of Eculizumab (Soliris) and Iduronate-2-Sulfatase (Elaprase). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A431. https://doi.org/10.1016/j.jval.2014.08.1098
Paul, A, et al. "Global HTA Assessments of Ultra-Orphan Products: A Case Study Of Eculizumab (Soliris) and Iduronate-2-Sulfatase (Elaprase)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A431. doi: https://doi.org/10.1016/j.jval.2014.08.1098
Paul A, Morawski J, Spinner DS, Doyle JJ, Faulkner EC, Ransom JF. Global HTA Assessments of Ultra-Orphan Products: A Case Study Of Eculizumab (Soliris) and Iduronate-2-Sulfatase (Elaprase). Value Health. 2014 Nov;17(7):A431. doi: 10.1016/j.jval.2014.08.1098. Epub 2014 Oct 26. PMID: 27201127.
Copy
Download .nbib